HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NRXP), Monday announced the signing of a Binding Term Sheet of $27 million with Smith & Sauer, LLC.
Of the total amount, $25 million will be used for Series A Preferred Stock purchase in HOPE to fund its planned clinic acquisitions, and the remaining will be used to advance NRx's new drug applications for NRX-100 and NRX-101. Investor will also purchase 500,000 NRx shares from existing shareholders for $2.75 per share
Under the agreement, Smith & Sauer will receive warrants to purchase 3 million unregistered shares of NRx common stock at $3 per share with a 24-month term. It will also receive royalties on net revenues from NRx product sales to a defined rate of return.
The collaboration is intended to bring innovative and accessible solutions to address mental health issues, Anita Nunes, Co-Founder of Smith & Sauer, stated.
Currently, NRx's stock is trading at $2.90, up 8.09 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.